The company, which is developing cancer treatments, plans to trade on the Nasdaq Global Market.
The number of changes being implemented by the new administration in the White House are likely too many to count. And while many are significant, one strikes a chord with the scientific community in a very meaningful way. In the days leading up to his inauguration, President Biden made it clear that science is a priority. He has backed that up with several recent announcements.
Alexandria LaunchLabs™ in Maryland, will provide fully equipped, affordable laboratory/office space with flexible lease terms, supporting infrastructure, access to amenities, and supporting services and programming through the project’s consortium of world-class partners, including Alexandria Venture Investments, BioHealth Innovation, Montgomery County, and the City of Gaithersburg. This unique, startup environment will accelerate the growth of local early-stage life science companies.
A nonprofit is considering Montgomery County as the site of a global pandemic center that would focus on prevention, research and response.
The Global Pandemic Prevention and Biodefense Center would serve as the “world’s epicenter” for pandemic prevention and biodefense ecosystem coordination.
County Council Member Hans Riemer proposed a $500,000 special appropriation to help fund the strategy phase of the project, which began in December. The appropriation was introduced at the council’s meeting on Tuesday.
GERMANTOWN, Md., Jan. 22, 2021 /PRNewswire/ — Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $7.50 per share. Precigen has also granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $112.5 million, excluding any exercise of the underwriters’ option. The offering is expected to close on January 26, 2021, subject to customary closing conditions.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) — Cerecor Inc. (“Cerecor”; NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today the exercise by the underwriters of their option to purchase an additional 1,648,812 shares of Cerecor’s common stock, $0.001 par value (the “Common Stock”) at a price to the public of $2.60 per share, increasing the total offered through the previously announced underwritten public offering to 13,971,819 of Common Stock and 1,676,923 of prefunded warrants. The gross proceeds to Cerecor from this exercise were approximately $4.3 million, resulting in approximately $40.7 million total gross proceeds from the offering. Cerecor intends to use the proceeds of the offering for general corporate purposes and working capital, primarily to support the ongoing clinical development of key assets within its pipeline and for general and administrative expenses.
CIT is conducting a competitive solicitation for young Virginia companies that have strong potential to drive economic growth in Virginia, including revenue and job creation, in strategically important industry sectors. The CCF FY21 round will provide grants up to $100,000 to advance companies and their highly promising technologies that have seen traction, for instance through revenue and/or investment, and would be catalyzed by support to commercialize the technologies or access the market. Up to $7 million has been allocated for the single FY21 round. Projects are anticipated to be 6-12 months and CCF funding can supports companies’ commercialization goals through product or service development, pilots, intellectual property protection, marketing, and more.
The moves come after an uncertain period for the Germantown biotech.
Image: Tim Goodnow is president and CEO of Germantown-based Senseonics. JOANNE S. LAWTON
Germantown, Maryland, and Hilden, Germany, January 20, 2021 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections – and will continue to closely monitor their performance as global concerns mount regarding the detection of new viral variants by established testing methods.
QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases since May 2020. A latest round of assessments conducted in January 2021 again confirmed that no recorded mutations affected the sensitivity of QIAGEN assays for detection of SARS-CoV-2. Surveillance of genetic variations will continue on a biweekly basis.
University research labs are playing a central role in the development of quantum technologies, such as quantum computers and quantum communication devices. Universities often approach quantum science from a number of angles. Some are good at theoretical approaches to quantum science. Some are strong at applied quantum science. Some focus on the educational and outreach of quantum physics.
Image: Research labs, like this one at the University of Waterloo’s Institute for Quantum Computing, are the heart of the world’s growing quantum industry.